On November 5, on the occasion of the opening of the China International Import Expo, a press conference on traditional Chinese medicine products of the China Belarus Industrial Park and the signing ceremony of the park cooperation agreement jointly sponsored by the Embassy of Belarus in China, the China Belarus Industrial Park Development Company and the national brand engineering office of Xinhua News Agency were held in Shanghai.

First deputy prime minister snopkov of Belarus, Ren Hongbin, deputy director of the state owned assets supervision and Administration Commission of the State Council, Yao Jian, deputy director of the Liaison Office of the central government in the Macao Special Administrative Region, Luan Xin, vice mayor of Qingdao, Gong Xixiang, member of the Party group and Secretary General of Xinhua news agency, Xie Xiaoyong, Chinese ambassador to Belarus, Xianke, Belarus ambassador to China, nikkinna, Deputy Minister of economy of Belarus Andrashuk, Vice Minister of health of Belarus, Zhou xingting, chairman of south Guangdong group, Cai Chuanqing, President of Jintai Academy of culture and chairman of new era Biotechnology Co., Ltd., attended the meeting and delivered speeches on site or online.

The novel coronavirus pneumonia, the first Chinese medicine for treating the new crown pneumonia, was officially released. At the signing ceremony, Nanyue Group signed a cooperation agreement with Jintai Cultural Academy and new era Biotechnology Co., Ltd. to introduce the same prescription medicine with the same name of "Linglan epidemic Qing" to settle in Macao for registration declaration, local manufacturing and global sales, work together to build an international whole industry chain service platform of traditional Chinese medicine, and strive to promote the standardization, scientization and internationalization of traditional Chinese medicine industry.

▶ The world's first novel coronavirus pneumonia special treatment for Chinese Medicine

The novel coronavirus pneumonia (Qing Qing Capsule) is the first Chinese patent medicine for treating new crown pneumonia in the world, which is developed by the new era biotechnology company of the Chinese medicine enterprise of the China White Industrial Park. According to introducing, "Ling Lan Qing Qing" series of preparations originated from the classical prescription in the treatise on febrile diseases before 1800. It integrated the successful experience of China's traditional medicine against malignant infectious diseases and combined with modern medicine, it was aimed at the rapid propagation of COVID-19, the rapid development of the disease, the high mortality rate and the many sequelae. The novel coronavirus pneumonia can effectively inhibit COVID-19, reduce the damage of COVID-19 to human organs and immune system, and then improve the immunity and restore the body function to achieve the purpose of treating new crown pneumonia.

"The Ministry of health in Belarus has registered the Qing Yan capsule in a very short time and listed it as an important strategic drug in Belarus for COVID-19's prevention and treatment." Nicola Snow, Pkov's first deputy prime minister, said in his speech, "we have seen the prospect of the pharmaceutical industry in the joint efforts of wisdom and technological innovation of TCM". "The Ministry of health of the Belarus has said that"

▶ Nanyue group plans to introduce "Linglan epidemic Qing" to be registered and manufactured in Macao and sold worldwide

According to the cooperation agreement, the "Linglan epidemic clearing" (qingepidemic capsule) to be introduced by Nanyue group is expected to become the first approved new crown Chinese patent medicine for treatment after the formal implementation of Macao's traditional Chinese medicine activities and Chinese patent medicine registration law, realize Macao's production and manufacturing, and make full use of Macao's "double circulation" hub advantages to export to the global market.

In his speech, deputy director Yao Jian fully affirmed the important contribution of south Guangdong group to the cooperation between Guangdong and Macao to promote the high-quality development of traditional Chinese medicine industry and the "going global" of traditional Chinese medicine. He believed that the cooperation and signing between south Guangdong group and new era biotechnology company would be helpful for the two sides to carry out international strategic cooperation in traditional Chinese medicine industry and promote the interaction and exchange of traditional Chinese medicine industry resources between the two sides in the future, It will play an important role in promoting complementarity and mutual enjoyment of industrial policies. As in the past, one belt, one road, will be a joint venture between Macao and Macao. The joint office of the China Central Government will always support the development of Macao's economy in an appropriate way, and support the two sides to strengthen exchanges and cooperation and promote greater progress in the "one belt and one Road" development.

At the event site, chairman Zhou xingting strongly recommended Macao's comprehensive advantages in developing traditional Chinese medicine to all guests, and sincerely invited the world's major health advanced enterprises and high-quality products of traditional Chinese medicine to settle in Macao. He said that the south Guangdong group always keeps in mind its original mission of supporting the moderately diversified development of Macao's economy, gives full play to the resource advantages of Guangdong Macao cooperation, and has built a large health industrial park of traditional Chinese Medicine - south Guangdong science and Technology Park, which has the most complete industrial development foundation and the greatest development potential in Macao, covering global direct acquisition of raw materials, global patent cooperation, Macao registration application The whole industry chain service platform for the great health of traditional Chinese medicine, which is manufactured and tested in Macao and sold in multiple ways around the world, is accelerating to become an important engine to promote the development of traditional Chinese medicine industry in Macao. Nanyue group will continue to provide customized services for global industry customers in new drug registration and application, R & D transformation and manufacturing and global diversified sales in Macao, realize resource sharing and complementary advantages with various scientific research institutions and traditional Chinese medicine enterprises, and make full use of modern technology to promote the inheritance, innovation and international development of traditional Chinese medicine.

Contributed by: Nanyue natural medicine company

Unified draft: south Guangdong Group Office

Edited / published by: Nanyue Group Office